RESUMEN
Objective To investigate the effect of thymus peptide five on infiltrating lymphocytes in the microenvironment of breast cancer with neoadjuvant chemotherapy.Methods From January 2012 to January 2014,80 breast cancer patients received neoadjuvant chemotherapy admitted to our hospital were studied and were randomly assigned into a study group or a control group.All patients received neoadjuvant chemotherapy,while the study group received thymus peptide five during neoadjuvant chemotherapy.Surgical resection of tumor tissue were performed in all patients after neoadjuvant chemotherapy and tumor tissue were collected.The CD4 + T cells,CD8 + T cells,and the proportion of CD4 +/CD8 + T cells in peripheral blood and tumor tissue,the peripheral blood IL-6,IL-t0 and TGF-β1 level were observed.Results When compared with the control group,CD4 +T cells in the study group decreased significantly (21.47％ ±3.29％ vs 23.88％ ±3.43％,P=0.002);CD8+ T cell increased apparently (30.36％ ±4.38％ vs 28.43％ ±4.16％,P-0.047);and the proportion of CD4 +/CD8 + T cells decreased respectively (0.71-± 0.14 vs 0.84 ± 0.18,P =0.001).There were no significant differences in peripheral blood CD4 +T cells,CD4 +/CD8 +T cells,IL-6,IL-10,TGF-β1 between the two groups before treatment (P ＞ 0.05).When compared with the control group,patients in the study group got an elevated postoperative level of CD4 + T cells in peripheral blood (27.67％-±4.24％ vs 25.09％ ±3.68％,P=0.005);a higher level ofCD4 +/CD8 +T (0.83 ±0.14 vs 0.75 ±0.18,P =0.029);an increase in IL-6 level (12.39 ±2.87 vs 9.24 ±3.38ng/L,P =0.000);a decrease in IL-10 (8.49 ±2.59 vs 12.59 ± 3.65ng/L,P=0.006);and adecrease in TGF-β1 (12.47±3.88 vs 17.76 ± 4.12ng/ml,P=0.000).There were no significant differences between the two groups in hospital duration,incision infection,surgical site bleeding,recurrence rate and mortality (P ＞ 0.05).Conclusion Thymus peptide five combined with neoadjuvant chemotherapy might be helpful to improve the immune status in the microenvironment and the total immune function in patients with breast cancer.
RESUMEN
Objective To investigate the effect of thymus peptide five on infiltrating lymphocytes in the microenvironment of breast cancer with neoadjuvant chemotherapy.Methods From January 2012 to January 2014,80 breast cancer patients received neoadjuvant chemotherapy admitted to our hospital were studied and were randomly assigned into a study group or a control group.All patients received neoadjuvant chemotherapy,while the study group received thymus peptide five during neoadjuvant chemotherapy.Surgical resection of tumor tissue were performed in all patients after neoadjuvant chemotherapy and tumor tissue were collected.The CD4 + T cells,CD8 + T cells,and the proportion of CD4 +/CD8 + T cells in peripheral blood and tumor tissue,the peripheral blood IL-6,IL-t0 and TGF-β1 level were observed.Results When compared with the control group,CD4 +T cells in the study group decreased significantly (21.47％ ±3.29％ vs 23.88％ ±3.43％,P=0.002);CD8+ T cell increased apparently (30.36％ ±4.38％ vs 28.43％ ±4.16％,P-0.047);and the proportion of CD4 +/CD8 + T cells decreased respectively (0.71-± 0.14 vs 0.84 ± 0.18,P =0.001).There were no significant differences in peripheral blood CD4 +T cells,CD4 +/CD8 +T cells,IL-6,IL-10,TGF-β1 between the two groups before treatment (P ＞ 0.05).When compared with the control group,patients in the study group got an elevated postoperative level of CD4 + T cells in peripheral blood (27.67％-±4.24％ vs 25.09％ ±3.68％,P=0.005);a higher level ofCD4 +/CD8 +T (0.83 ±0.14 vs 0.75 ±0.18,P =0.029);an increase in IL-6 level (12.39 ±2.87 vs 9.24 ±3.38ng/L,P =0.000);a decrease in IL-10 (8.49 ±2.59 vs 12.59 ± 3.65ng/L,P=0.006);and adecrease in TGF-β1 (12.47±3.88 vs 17.76 ± 4.12ng/ml,P=0.000).There were no significant differences between the two groups in hospital duration,incision infection,surgical site bleeding,recurrence rate and mortality (P ＞ 0.05).Conclusion Thymus peptide five combined with neoadjuvant chemotherapy might be helpful to improve the immune status in the microenvironment and the total immune function in patients with breast cancer.
RESUMEN
Objective To investigate the clinical diagnostic significance of detecting T in peripheral blood lymphocyte subsets (CD4+,CD8+ and the ratio of pulmonary tuberculosis with diabetes) and explore drug therapy of the five thymus peptide combined anti-tuberculosis on the diabetes complicated with pulmonary tuberculosis.Methods Eighty cases of pulmonary tuberculosis complicated with diabetes mellitus were selected as our treatment subject,who were treated with anti-tuberculosis drug treatment and five thymus peptide regulating immunity treatment.T lymphocyte subsets (CD4 +,CD8 + and their ratio) were detected.Meanwhile acid-fast bacilli and image detection were performed.Another 80 cases were as our control group that treated with anti-tuberculosis drug.Results Following the thymus peptide five treatment for 1,2,and 6 months,T lymphocyte subsets were (CD4+:(34.34 ± 7.32) ％,(39.23 ± 6.62) ％,(41.06 ± 7.13) ％),(CD8+:(31.42 ±8.91)％,(32.52 ±8.58)％,(32.12 ±8.59)％),(CD4+/CD8+:(1.23 ±0.31),(1.34 ±0.30),(1.36 ± 0.32),higher than that of before treatment (30.26 ± 8.25) ％,(30.36 ± 9.86) ％,(1.13 ± 0.42) CD4 +.Through 2 months treatment,CD4+,CD4+/CD8+ of patient in treatment groups were different with that of control group (P ＜ 0.01 or P ＜ 0.05).80 patients after anti-TB plus application thymopentin regulating immunity for 2 months,normal sputum negative conversion rate of CD4+ was 97.2％ and improvement rate was 98.0％.However cases with high CD4+ T lymphocyte subsets showed 78.6％ negative rate of acid-fast bacilli and 88.0 ％ cured rate,and there was significant difference (x2 =4.764,7.680,respectively,P ＜ 0.05).Conclusion Thymic peptide five might have the ability of improving the cellular immune function in patients with pulmonary tuberculosis and diabetes.The prognosis is better when T lymphocyte subsets CD4+ of patient was back to normal through treatment.
RESUMEN
Objective To observe the effect of thymic peptide on the serum levels of IL-10 and IFN-? in patients with varruca planea and the effect of treatment.Methods Double-antibody sandwich ELISA was used to detect the serum levels of interleukin-10(IL-10) and interferon-gamma(IFN-?) in normal persons and varruca planea patients with thymic peptide and control before and after treatment.Results Before treatment,the serum levels of IL-10 were significantly higher in patients,while the levels of IFN-? were significantly lower than that in normal people(P0.05).The levels of IL-10 in the thymic peptide group were lower than those of control group,while the levels of IFN-? were higher than those of control group after treatment (p